•
Sep 30, 2020

AptarGroup Q3 2020 Earnings Report

AptarGroup's Q3 2020 results reflected an increase in sales and core sales, driven by the Pharma segment and growth in food, personal care, and home care markets, while beauty and beverage markets were impacted by COVID-19.

Key Takeaways

AptarGroup reported an 8% increase in sales to $759 million with a 2% increase in core sales during Q3 2020. The Pharma segment showed strong growth, while Beauty and Beverage segments were impacted by COVID-19. Earnings per share increased to $0.95, and adjusted earnings per share rose to $1.00.

Reported sales increased 8%, including positive effects of currency translation rates and recent acquisitions, and core sales increased 2%.

Strong reported and core growth in the Pharma segment.

Core sales growth in the food, personal care and home care markets.

Reported earnings per share totaled $0.95 (an increase of 12% compared to the prior year), and adjusted earnings per share totaled $1.00 (an increase of 3% compared to the prior year).

Total Revenue
$759M
Previous year: $701M
+8.3%
EPS
$1
Previous year: $0.93
+7.5%
Total Core Sales Growth
2%
Pharma Core Sales Growth
11%
Gross Profit
$279M
Previous year: $257M
+8.7%
Cash and Equivalents
$227M
Previous year: $271M
-16.3%
Free Cash Flow
$103M
Previous year: $97.2M
+6.4%
Total Assets
$3.86B
Previous year: $3.47B
+11.4%

AptarGroup

AptarGroup

AptarGroup Revenue by Segment

Forward Guidance

Aptar expects to continue to achieve core sales growth in the fourth quarter, with rising demand in many end markets expected to more than offset COVID-19 related declines in some other end markets. Aptar expects earnings per share for the fourth quarter of 2020, excluding any restructuring expenses and acquisition-related costs, to be in the range of $0.84 to $0.92.

Positive Outlook

  • Company expects to continue to achieve core sales growth in the fourth quarter.
  • Rising demand in many end markets is expected to more than offset COVID-19 related declines in some of our other end markets.
  • Company is proud of the way our employees have responded to the difficult year and we are performing well.
  • Company expects our Pharma business to continue to do well with existing business
  • Company expects increased opportunities directly and indirectly related to the pandemic

Revenue & Expenses

Visualization of income flow from segment revenue to net income